Recently, Selinexor, an oral XPO1 inhibitor, has emerged as a promising reagent for relapsed or refractory multiple myeloma (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212306). The gene discussed is XPO1; the disease is plasma cell myeloma.